Additional file 1 of A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs

Additional file 1: Figure S1. The cohort of Shiba Inu dogs tested in this study (a). Twelve skin swab samples and a faecal sample were collected from each dog in each group, resulted in a total of 12 ´ (10+ 10+ 10 + 20) = 600 skin swab samples and 1 ´ (10+ 10 + 10 + 20) = 50 faecal samples. The twelve skin sites include a buccal sample was collected from three groups; cADpre, cADtreat and Healthy, 1 ´ (10+ 10 + 20) = 40 samples. The twelve skin sites are shown in (b); 1. perilabial area (lips), 2. medial pinnae (concave pinnae), 3. axilla, 4. front paw (dorsal and palmar sides combined), 5. hind paw (dorsal and palmar sides combined), 6. cubital flexor (elbow fold), 7. palmar metacarpal (from carpal to metacarpal pad), 8. flank, 9. inguinal area (groin), 10. abdomen, 11. perineum (from genitalia to anus) and 12. ventral tail (proximal). Age distribution of the participating dogs (c), CADESI-04 (d) and PVAS (e) values for each dog were plotted in the graphs. The values of healthy dogs were given as 0. Asterisks (*) indicate the statistically significant difference; **p < 0.01, ***p < 0.001, ****p < 0.0001 (Kruskal-Wallis test). Ten dogs with untreated cAD dogs (cADpre) received oclacitinib treatment for 2 weeks (cADpost). The treatment efficacy was shown as a statistically significant reduction in CADESI-04 (**p < 0.01, Wilcoxon test; f) and PVAS values (p = 0.0078, Wilcoxon test; g). For these 10 dogs, the CADESI-04 score in 12 different skin sites, the perilabial area, medial pinna, axilla, front paw, hind paw, cubital flexor, palmar metacarpal, flank, inguinal area, abdomen, perineum, and ventral tail, is shown in (h). A significant reduction of CADESI-04 score was observed in inguinal area (*p < 0.05; two-way ANOVA).

附加文件1：图S1。本研究受试的柴犬（Shiba Inu）队列(a)。每组每只犬采集12份皮肤拭子样本与1份粪便拭子样本，最终共获得12×(10+10+10+20)=600份皮肤拭子样本，以及1×(10+10+10+20)=50份粪便拭子样本。其中，针对cADpre、cADtreat与健康组3个组别采集颊部样本，共计1×(10+10+20)=40份样本。12个皮肤采样部位详见(b)：1. 唇周区域（唇部），2. 耳内侧（耳廓凹陷面），3. 腋下，4. 前爪（背侧与掌侧合并采样），5. 后爪（背侧与掌侧合并采样），6. 肘屈部（肘窝），7. 掌骨掌侧区（腕部至掌骨垫区域），8. 胁腹部，9. 腹股沟区（腹股沟），10. 腹部，11. 会阴部（生殖器至肛门区域），12. 尾腹侧（近端段）。对受试犬的年龄分布(c)、每只犬的CADESI-04评分(d)与PVAS评分(e)进行可视化绘图，健康犬的评分设定为0。星号(*)代表统计学显著性差异：**p<0.01，***p<0.001，****p<0.0001（Kruskal-Wallis检验）。10只未接受治疗的犬特应性皮炎（canine atopic dermatitis, cAD）患犬（cADpre组）接受奥克拉替尼（oclacitinib）治疗2周，对应组别为cADpost组。治疗效果表现为CADESI-04评分（**p<0.01，Wilcoxon检验；f）与PVAS评分（p=0.0078，Wilcoxon检验；g）均出现具有统计学意义的降低。针对这10只犬，其12个不同皮肤部位的CADESI-04评分结果详见(h)，涉及部位包括唇周区域、耳内侧、腋下、前爪、后爪、肘屈部、掌骨掌侧区、胁腹部、腹股沟区、腹部、会阴部与尾腹侧。结果显示腹股沟区的CADESI-04评分出现显著降低（*p<0.05；双因素方差分析（two-way ANOVA））。